Source - LSE Regulatory
RNS Number : 0769S
SkinBioTherapeutics PLC
07 March 2023
 

 SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

AxisBiotix-Ps™ receives health authority approval for European market launch

 

·    First European launch for Axis-BioTix-Ps™ is in Spain from 13 March

·    Next targets include Italy and then France

·    Broader launch presents further validation of the benefits of this product and opens new geographical revenue streams

7 March 2023 - SkinBioTherapeutics plc (AIM: SBTX), a life science business focused on skin health, has announced the launch of AxisBiotix-Ps™, a food supplement to alleviate the symptoms associated with Psoriasis, into the Spanish market.

Health authority authorisation in Spain was received on 3 March 2023 paving the way for the AxisBiotix-Ps™ supplement to be made available from 13 March 2023.  Building on the initial launch in the UK where customer retention rates have risen to 80%+1, the launch of AxisBiotix-Ps into new markets in Europe is the next milestone in its commercialisation strategy.

Sales in this new market will be managed directly by the AxisBiotix team in the UK, with products being distributed through the Company's EU hub in the Netherlands. Products will be sold through a country-specific website,  with names and requisite labelling appropriate for the Spanish market and allowing opportunities for an expanded product range in future.

The Spanish market presents an exciting opportunity for AxisBiotix-Ps where approximately 60% of people have sensitive skin and, like the UK, between 1-3% of these sufferers have psoriasis. The Company believes primary users will be those seeking natural methods to manage sensitive skin conditions associated with psoriatic skin. Data about Spain's population also shows that people are receptive to food supplements to improve health and wellness, with approximately 7 in 10 currently using them.  

The next target countries for launch are Italy and then France. Talks with the individual country regulators are currently underway and we expect commercialisation will commence during the year.

Stuart J. Ashman, CEO of SkinBioTherapeutics, said: "Our aim with AxisBiotix-Ps™ is to offer people a natural way to help them manage their skin health that is self-delivered and fits within their everyday life. AxisBiotix-Ps has seen high customer retention in the UK market. If we receive a similar reception in Spain and other European markets, this would present further validation of the benefits of this product and opens new geographical revenue streams for the Company. A successful launch in this new market also provides additional evidence to support ongoing discussion with potential partners."

Psoriasis is a lifelong condition, with no known cure, which impacts the everyday lives of sufferers. Existing treatments such as steroids or immuno-suppressants cannot be used over the long-term, which makes AxisBiotix-Ps an effective solution to alleviate its symptoms. As a food supplement, AxisBiotix-Ps is based on strong scientific data regarding the gut-skin axis, re-introducing missing bacteria into the gut and redressing the balance to improve skin health.

1: As reported in the Full Year results dated 15 December 2022

-Ends-

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

For more information please contact:

 

SkinBioTherapeutics plc

Stuart J. Ashman, CEO

Manprit Randhawa, CFO

Tel: +44 (0) 191 495 7325

Cenkos Securities Plc (Nominated Adviser & Broker)

Giles Balleny, Max Gould (Corporate Finance)

Dale Bellis, Tamar Cranford-Smith (Sales)

Tel: +44 (0) 20 7397 8900

Instinctif Partners (financial press)

Melanie Toyne-Sewell / Tim Field  / Adam Loudon

Tel: +44 (0) 20 7457 2020

SkinBioTherapeutics @instinctif.com

 

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK.

For more information, visit: www.skinbiotix.com and www.axisbiotix.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFFFLFVAIRIIV
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Skinbiotherapeutics PLC (SBTX)

0p (0.00%)
delayed 15:57PM